In this video, Scarlett Gomez, MD, PhD, discusses the significance of the private public collaboration between the National Cancer Institute’s Surveillance Epidemiology, and End Results program and the Oncotype DX Genomic Prostate Score assay in investing patterns in prostate genomic testing.Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.
Destigmatizing Urology: Dr. Pruthi discusses mental health
May 23rd 2022“I think we often encourage our patients to share concerns about depression, anxiety, and other mental health conditions, yet are less likely ourselves to seek help due to this issue of stigma,” says Raj S. Pruthi, MD, MHA, FACS.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.